FrancophonIA/ELRC3.0 huggingface dataset:
English: T12/PR48: INCIVO for 12 weeks with peginterferon alfa-2a and ribavirin for 48 weeks; Pbo/PR: placebo for 12 weeks with peginterferon alfa-2a and ribavirin for 48 weeks
Estonian: T12/PR48: INCIVO 12 nädalat ja alfa-2a-peginterfoon pluss ribaviriin 48 nädalat; Pbo/PR: platseebo 12 nädalat ja alfa2a- peginterfoon pluss ribaviriin 48 nädalat
English: amlodipine, diltiazem, felodipine, nicardipine,
Estonian: amlodipiin, diltiaseem, felodipiin, nikardipiin, nifedipiin, nisoldipiin, verapamiil vererõhu langetamiseks (kaltsiumikanali blokaatorid)
English: 3 at screening.
Estonian: 4.7 Toime reaktsioonikiirusele
English: Refer to the Summary of Product Characteristics for ribavirin and peginterferon alpha for additional
Estonian: Lisainfo saamiseks vaadake ribaviriini ja alfapeginterferooni ravimi omaduste kokkuvõtteid.
English: España
Estonian: Danmark
English: See also the package leaflets for peginterferon alfa and ribavirin for side effects reported for these
Estonian: Vaadake ka alfapeginterferooni ja ribaviriini pakendi infolehtedelt nende ravimite kõrvaltoimeid.
English: abacavir
Estonian: repagliniid
English: Use in patients with advanced liver disease
Estonian: Maksatsirroosiga patsiendid
English: and patients receiving telaprevir 750 mg every 8 hours (q8h).
Estonian: ↓ telapreviir 750 mg iga 8h järel
English: oral midazolam*
Estonian: BENSODIASEPIINID alprasolaam*
English: Table 10 shows SVR rates by extent of liver fibrosis at baseline.
Estonian: Tabelis 10 on näidatud SVR määrad ravieelse
English: In patients with HCV RNA between 100 IU/ml and 1,000 IU/ml at week 12,
Estonian: Patsientidest, kellel oli 12. ravinädalal HCV RNA tase vahemikus 100 IU/ml kuni 1 000 IU/ml, saavutas püsiva ravivastuse 2/8 (25%).
English: It is not recommended to co-administer lopinavir/ritonavir and telaprevir (see section 4.4).
Estonian: Lopinaviir/ritonaviiri ja telapreviiri ei ole soovitatav koos manustada (vt lõik 4.4).
English: Use of peginterferon alfa 2a or 2b Two types of peginterferon alfa (2a and 2b) were studied in the Phase 2a open label, randomised
Estonian: Alfapeginterferooni kahte tüüpi (2a ja 2b) uuriti teise faasi avatud randomiseeritud uuringus C208 varem ravi mitte saanud patsientidel.
English: CY-2234 Λευκωσία Τηλ: +357 22 207 700
Estonian: CY-2234 Λευκωσία
English: Caution is warranted and clinical monitoring is recommended when co-administered with INCIVO.
Estonian: Samaaegsel manustamisel koos INCIVO'ga on nõutav ettevaatus ja soovitatav kliiniline jälgimine.
English: See also the Summary of Product
Estonian: Vaadake ka ribaviriini ravimi omaduste kokkuvõtet.
English: • The Summary of Product Characteristics
Estonian: • Riski minimeerimise lisameetmed
English: Special populations
Estonian: Muud kombinatsioonid
English: Therefore, herbal preparations containing St John's wort
Estonian: Infektsioonid ja infestatsioonid sage suu kandidiaas
English: Undetectable HCV RNA (target not detected) at
Estonian: Allpool määramispiiri olev HCV RNA (sihtväärtus määramatu) nädalal 4
English: Follow usual aseptic procedures.
Estonian: Järgida tavalisi aseptika nõudeid.
English: After administration of a double dose, local reactions may increase slightly.
Estonian: Pärast kahekordse doosi manustamist, võivad lokaalsed reaktsioonid veidi tugevneda.
English: Following the second vaccination swelling may persist for at least 35 days.
Estonian: Pärast teist vaktsineerimist võib turse püsida vähemalt 35 päeva.
English: If you notice any serious effects or other effects not mentioned in this leaflet, please inform your
Estonian: Kui täheldate tõsiseid kõrvaltoimeid või muid toimeid, mida pole käesolevas pakendi infolehes mainitud, palun teavitage sellest oma veterinaararsti.
English: Intervet International B.V. Wim de Körverstraat 35 5831AN Boxmeer The Netherlands
Estonian: Wim de Körverstraat 35 5831 AN Boxmeer Holland
English: No systemic reactions to vaccination were seen following intramuscular vaccination.
Estonian: Vaktsineerimisjärgseid süsteemseid reaktsioone ei ole täheldatud pärast intramuskulaarset vaktsineerimist.
English: Store and transport refrigerated (2ºC - 8°C).
Estonian: Hoida ja transportida külmas (2C...8C).
English: Vaccination may result in moderate swelling of the breast tissue which will resolve within 30 days.
Estonian: Vaktsineerimine võib põhjustada mõõdukat rinnalihase turset, mis taandub 30 päeva jooksul.
English: Accidental injection is dangerous - read package leaflet before use.
Estonian: Juhuslik süstimine on ohtlik - enne kasutamist lugege pakendi infolehte.
English: 500ml high density polyethylene (HDPE) flexible bottle closed with a chlorobutyl rubber closure held in place with an aluminium seal with centre hole.
Estonian: 500ml kõrge tihedusega polüetüleenist (HDPE) elastne pudel klorobutüülkummist korgiga, mida hoiab paigas alumiiniumkate, millel on auk keskel.
English: Triethanolamine (at doses up to 0.25 mg/kg bw) is considered not within the scope of Council
Estonian: Trietanoolamiin (doosis kuni 0,25 mg/kg kehamassi kohta) ei kuulu Nõukogu regulatsiooni (EEC) nr. 2377/90 kohaldamisalasse.
English: A second dose of 0.5 ml should be administered 4 to 10 weeks after the first vaccination.
Estonian: Teine doos (0,5 ml) tuleb manustada 4 kuni 10 nädalat pärast esimest.
English: The second dose should be administered no later than 6 weeks before the onset of lay.
Estonian: Teine doos manustada mitte hiljem kui 6 nädalat enne munemisperioodi algust.
English: Pack sizes:
Estonian: Abiained:
English: Efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.
Estonian: Ravimi efektiivsust tõestati tibude katselisel nakatamisel umbes 3 nädalat pärast koorumist.
English: According to Article 71 of Directive 2001/82/EC as amended, Member States prohibit or may prohibit the import, sale, supply and/or use of the veterinary medicinal product on the whole or part of their a) the administration of the veterinary medicinal product to animals will interfere with the implementation of a national programme for the diagnosis, control and eradication of animal disease, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals b) the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.
Estonian: Vastavalt Euroopa Parlamendi ja nõukogu direktiivi nr 2001/82/EÜ artiklile 71 keelustavad või võivad keelustada liikmesriigid veterinaarravimi impordi, müügi, tarnimise ja/või kasutamise oma territooriumil või osal oma territooriumist, kui on tuvastatud, et:
English: The duration of passive transfer of immunity: 51 weeks following completion of the vaccination
Estonian: Passiivse immuunsuse edasiandmise kestus: 51 nädalat pärast täielikku vaktsineerimist.
English: Withdrawal period: Zero days
Estonian: Keeluajad: 0 päeva.
English: One dose of 0.5 ml should be given at 10 to 14 weeks of age.
Estonian: Üks doos ( 0,5 ml) manustatakse 10. kuni 14. elunädalal.
English: Vaccine against necrotic enteritis
Estonian: Vaktsineerimine nekrootilise enteriidi vastu.
English: To stimulate active immunity in chickens, in order to provide passive protection to the progeny against Clostridium perfringens Type A induced necrotic enteritis.
Estonian: Aktiivse immuunsuse stimuleerimiseks kanadel, et pakkuda passiivset kaitset nende järeltulijatele Clostridium perfringens tüüp A põhjustatud nekrootilise enteriidi eest.
English: Other provisions Annex II of Council Regulation (EEC)
Estonian: Kõik toiduks kasutatavad liigid Nõukogu määruse (EMÜ) nr 2377/90 II
English: The onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure
Estonian: Passiivse immuunsuse edasiandmise algus: 6 nädalat pärast täielikku vaktsineerimist.
English: For the active immunization of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.
Estonian: Kanade aktiivseks immuniseerimiseks, et anda nende järglastele passiivne immuunsus nekrootilise enteriidi vastu munemisperioodil.
English: Swelling was very common.
Estonian: Turset esines sageli.
English: Do not mix with any other veterinary medicinal product.
Estonian: Mitte segada teiste vaktsiinide ega immunoloogiliste ravimitega.
English: The vaccine is safe for use in laying and breeding birds.
Estonian: Vaktsiin on ohutu munevatele lindudele ja sugulindudele.
English: Shelf-life of the veterinary medicinal product as packaged for sale: 18 months.
Estonian: Müügipakendis veterinaarravimi kõlblikkusaeg: 18 kuud Kõlblikkusaeg pärast vahetu pakendi esmast avamist: 8 tundi.
English: Shelf-life after first opening the immediate packaging: 8 hours
Estonian: Kõlblikkusaeg pärast pakendi esmast avamist: kasutada 8 tunni jooksul.
English: Vaccinate chickens by the intramuscular route into the breast.
Estonian: Kanu vaktsineeritakse intramuskulaarselt rinnalihasesse.
English: Pack Sizes
Estonian: PAKENDI SUURUS
English: Special precautions to be taken by the person administering the veterinary medicinal product to
Estonian: Antud veterinaarravimit loomadele manustava isiku poolt rakendatavad spetsiaalsed ettevaatusabinõud
English: MINIMUM PARTICULARS TO APPEAR ON IMMEDIATE PACKAGING UNITS
Estonian: MIINIMUMNÕUDED ANDMETE OSAS, MIS PEAVAD OLEMA ÄRA MÄRGITUD VAHETUL SISEPAKENDIL
English: Do not use after the expiry date stated on the carton.
Estonian: Pärast pakendil märgitud kõlblikkusaja lõppu mitte kasutada.
English: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.
Estonian: Andmed antud vaktsiini kokkusobivuse kohta teiste vaktsiinidega puuduvad.
English: Pharmacotherapeutic group: Immunologicals for aves, ATC vet code: QI01AB08
Estonian: ATCvet kood: QI01AB08
English: Clostridium perfringens Type A alpha toxoid: ≥ 6.8 IU*
Estonian: Clostridium perfringens tüüp A alfa toksoid: ≥ 6.8 RÜ* Kerge mineraalõli: 0,31 ml
English: A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH
Estonian: A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(d) JA TOOTMISLOA HOIDJA(d), KES VASTUTAB (VASTUTAVAD) RAVIMIPARTII VÄLJASTAMISE EEST
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Estonian: TOIMEAINE(TE) JA ABIAINE(TE) SISALDUS
English: B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION
Estonian: B. MÜÜGILOA TINGIMUSED VÕI PIIRANGUD TARNIMISE VÕI KASUTAMISE OSAS
English: Syringes and needles must be sterile before use.
Estonian: Kasutada steriilseid süstlaid ja nõelu.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
Estonian: MÜÜGILOA HOIDJA NING, KUI NEED EI KATTU, RAVIMIPARTII VÄLJASTAMISE EEST VASTUTAVA TOOTMISLOA HOIDJA NIMI JA AADRESS
English: MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR
Estonian: BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(D) JA TOOTMISLOA HOIDJA(D), KES VASTUTAB (VASTUTAVAD) RAVIMIPARTII
English: Netvax emulsion for injection for chickens
Estonian: Netvax Süsteemulsioon kanadele
English: To reduce mortality and the incidence and severity of lesions caused by Clostridium perfringens Type A induced necrotic enteritis.
Estonian: Clostridium perfringens tüüp A põhjustatud nekrootilise enteriidi haigusjuhtude arvu ja raskusastme ning suremuse vähendamiseks.
English: SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
Estonian: ERINÕUDED ETTEVAATUSABINÕUDE OSAS KASUTAMATA JÄÄNUD PREPARAADI VÕI NENDE JÄÄTMETE, KUI NEID TEKIB, HÄVITAMISEL
English: This summary was last updated in 08-2011.
Estonian: Kokkuvõtte viimane uuendus: 08-2011.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Savene on 28 July 2006.
Estonian: Euroopa Komisjon väljastas Savene müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. juulil
English: Savene was not compared with any other medicines in these studies.
Estonian: Savenet nendes uuringutes teiste ravimitega ei võrreldud.
English: What is Savene?
Estonian: Mis on Savene?
English: Other information about Savene:
Estonian: Muu teave Savene kohta
English: The first infusion of Savene is given as soon as possible after the accident, and no later than six hours after it happened.
Estonian: Esimene Savene infusioon antakse niipea kui võimalik, kuid kuni 6 tunni jooksul pärast juhtumit.
English: Patients will be monitored for these side effects before, during and after treatment.
Estonian: Patsiente tuleb kõrvalnähtude osas jälgida enne ravi, ravi ajal ja pärast ravi.
English: The infusion should last between one and two hours, and be given at a site other than where the extravasation happened.
Estonian: Infusiooni kestus peaks olema 1-2 tundi ja see tuleks teha mujale kui ekstravasatsiooni tekkimise kohta.
English: The most common side effects with Savene (seen in more than 1 patient in 10) are nausea (feeling sick), and pain and infection at the site of the injection.
Estonian: Savene kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on iiveldus ning valu ja infektsioon süstekohal.
English: The Committee decided that Savene's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Savene kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: Anthracycline extravasation is a condition that can currently be managed using various methods, but for which there is no standard authorised treatment.
Estonian: Antratsükliinist põhjustatud ekstravasatsioon on seisund, mida võib praegu ravida mitmel viisil, kuid millele ei ole ette nähtud ametlikku standardset raviviisi.
English: Savene has been tested in two main studies involving a total of 80 patients who had extravasation of anthracyclines such as epirubicin or doxorubicin.
Estonian: Savenet uuriti kahes põhiuuringus, milles osales kokku 80 patsienti, kellel oli antratsükliinidest (doksorubitsiin või epirubitsiin) põhjustatud ekstravasatsioon.
English: For more information about treatment with Savene, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Savene ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is the risk associated with Savene?
Estonian: Mis riskid Savenega kaasnevad?
English: Two further infusions are then given, one on day 2 and another on day 3, at the same time as the first infusion.
Estonian: Kaks järgmist infusiooni antakse vastavalt 2. ja 3. päeval esimese infusiooni manustamisega samal kellaajal.
English: Only one patient among the 54 in whom the effectiveness of Savene could be measured had tissue damage requiring surgery.
Estonian: Ainult 1 patsiendil 54-st, kellel sai hinnata Savene tõhusust, tekkis kirurgilist ravi vajav koekahjustus.
English: For the full list of all side effects reported with Savene, see the package leaflet.
Estonian: Savene kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Savene dexrazoxane
Estonian: Savene deksrasoksaan
English: This document is a summary of the European public assessment report (EPAR) for Savene.
Estonian: Käesolev dokument on ravimi Savene Euroopa avaliku hindamisaruande kokkuvõte.
English: Because the number of patients who have extravasation of anthracyclines is low, the condition is considered ‘rare', and Savene was designated an ‘orphan medicine' (a medicine used in rare diseases) on 19 September 2001.
Estonian: Et antratsükliinidest tingitud ekstravasatsioonidega patsiente on vähe ja see seisund esineb harva, nimetati Savene 19. septembril 2001 harvikravimiks.
English: The CHMP concluded that Savene had shown its ability to treat anthracycline extravasation, allowing patients to continue their anticancer treatment.
Estonian: Inimravimite komitee otsustas, et Savene on osutunud efektiivseks antratsükliinist põhjustatud ekstravasatsioonide ravimisel, võimaldades patsientidel vähiravi saamist jätkata.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Savene.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Extravasation happens when an anticancer medicine that is normally injected into a vein leaks or is accidentally injected in the tissue surrounding the vein, where it can cause serious damage.
Estonian: Ekstravasatsioon (veresoonest väljumine) tekib, kui veeni süstitav vähiravim lekib soonest välja või seda süstitakse kogemata veeni ümbritsevasse koesse, kus see võib põhjustada raskeid kahjustusi.
English: Savene should not be used in people who may be hypersensitive (allergic) to dexrazoxane or any of the other ingredients.
Estonian: Savenet ei tohi kasutada patsiendid, kes võivad olla deksrasoksaani või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: What benefit has Savene shown during the studies?
Estonian: Milles seisneb uuringute põhjal Savene kasulikkus?
English: Dexrazoxane has been in use since the 1990s as a medicine to help prevent the cardiomyopathy (harm to the heart muscle) associated with the use of anthracyclines.
Estonian: Deksrasoksaani on kasutatud alates 1990. aastatest ravimina, mis aitab ennetada antratsükliinravimite kasutamisega seostatavat kardiomüopaatiat (südamelihase kahjustust).
English: Savene is a powder and diluent that are made up into a solution for infusion (drip into a vein).
Estonian: Savene on pulber ja lahjendi, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: The way it works is not entirely clear, but may be linked to the way the medicine attaches to iron in the body to form a ‘chelate' and to its effect on some enzymes, such as topoisomerase II.
Estonian: Selle toimemehhanism ei ole täiesti selge, kuid võib olla seotud selle seondumisega organismis leiduva rauaga (kelaatimine) ja toimega teatud ensüümidele (topoisomeraas II).
English: The studies looked at how many patients needed surgery to correct the damage due to the extravasation.
Estonian: Uuringutes vaadeldi, mitu patsienti vajas ekstravasatsioonist tingitud kahjustuse kõrvaldamiseks kirurgilist ravi.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Savene is available here.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Savene kohta on siin.
English: Together, these effects can reduce the amount of tissue damage caused by anthracycline extravasation.
Estonian: Need toimed vähendavad kokkuvõttes antratsükliinist põhjustatud ekstravasatsiooni tekitatud koekahjustuste määra.
English: Savene is used to treat extravasation of anthracyclines (a group of anticancer medicines).
Estonian: Savenet kasutatakse antratsükliinidest (vähiravimite rühm) tingitud ekstravasatsioonide raviks.
English: Why has Savene been approved?
Estonian: Miks Savene heaks kiideti?
English: Savene must be used under the supervision of a doctor who has experience in the use of anticancer medicines.
Estonian: Ravi Savenega peab toimuma vähiravimite kasutamises kogenud arsti järelevalve all.
English: It contains the active substance dexrazoxane.
Estonian: Savene sisaldab toimeainena deksrasoksaani.
English: How is Savene used?
Estonian: Kuidas Savenet kasutatakse?
English: Although this may be caused by their anti-cancer treatment, it can also be caused by Savene, because it is a cytotoxic (a medicine that destroys cells that are multiplying) that can affect the bone marrow.
Estonian: Patsiendil võib väheneda leukotsüütide ja trombotsüütide arv veres, see võib tuleneda osaliselt vähiravist, aga ka Savenest, sest see ravim on ise tsütotoksiline (hävitab paljunevaid rakke) ja võib mõjutada luuüdi.
English: How has Savene been studied?
Estonian: Kuidas Savenet uuriti?
English: What is Savene used for?
Estonian: Milleks Savenet kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Savene on retseptiravim.
English: It must not be used in women who could become pregnant or who are breastfeeding, or in patients receiving vaccination against yellow fever.
Estonian: toidavad rinnaga või keda vaktsineeritakse kollapalaviku vastu.
English: How does Savene work?
Estonian: Kuidas Savene toimib?
English: The full EPAR for Savene can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst Savene kohta on siin.
English: The active substance in Savene, dexrazoxane, is an antidote to anthracyclines.
Estonian: Savene toimeaine deksrasoksaan on antratsükliinide antidoot (vasturavim).
English: What measures are being taken to ensure the safe and effective use of Enzepi?
Estonian: Mis meetmed võetakse, et tagada Enzepi ohutu ja efektiivne kasutamine?
English: Enzepi is available as capsules (5,000; 10,000; 25,000 and 40,000 units).
Estonian: Enzepit turustatakse kapslitena (5000, 10 000, 25 000 ja 40 000 ühikut).
English: The full EPAR for Enzepi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Enzepi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Enzepi
Estonian: Muu teave Enzepi kohta
English: Capsules should be swallowed whole and not chewed or crushed.
Estonian: Kapslid tuleb neelata tervelt ja neid ei tohi närida ega purustada.
English: Treatment is started at a low dose, which the doctor may then increase slowly until an appropriate dose is reached.
Estonian: Ravi alustatakse väikese annusega, mida arst võib seejärel aeglaselt õige annuse saavutamiseni suurendada.
English: What is Enzepi and what is it used for?
Estonian: Mis on Enzepi ja milleks seda kasutatakse?
English: In one main study involving 96 patients, treatment with Enzepi led to the absorption of 84% of the fats consumed by patient over 72 hours compared with 85% absorption with the already authorised medicine.
Estonian: Ühes peamises uuringus, milles osales 96 patsienti, võimaldas ravi Enzepiga patsiendil 72 tunni jooksul 84% tarvitatud rasvade imendumise, olemasoleva müügiloaga ravimi korral imendus 85%.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Enzepi's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Enzepi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Enzepi was shown to be as effective as the already well-known marketed medicine.
Estonian: Enzepi osutus sama efektiivseks kui juba turustatud ravim.
English: In terms of safety, Enzepi's side effects are comparable to other marketed products.
Estonian: Ohutuse seisukohast on Enzepi kõrvalnähud võrreldavad teiste turustatud ravimite kõrvalnähtudega.
English: For patients who cannot swallow capsules, the capsules may be opened and the content mixed with a small amount of acidic food such as fruit puree which should be swallowed immediately without chewing.
Estonian: Patsiendid, kes ei saa kapsleid neelata, võivad kapsli avada ja segada selle sisu väikese koguse happelise toiduga (nt puuviljapüreega), mis tuleb seejärel kohe ilma närimata sisse võtta.
English: In clinical trials most side effects were mild to moderate in severity.
Estonian: Kliinilistes uuringutes oli enamik kõrvalnähte kerged kuni mõõdukad.
English: Enzepi will therefore help the body absorb nutrients better, especially fats.
Estonian: Seega aitab Enzepi kehal paremini toitaineid omastada, eriti rasvu.
English: Enzepi should be taken during meals or snacks with a drink of water or juice.
Estonian: Enzepit tuleb võtta toidukorra ajal koos vee või mahlaga.